Effect of Aflibercept (Eylea®) in the Management of Bevacizumab (Avastin®) Resistant Diabetic Macular Edema
Phase of Trial: Phase IV
Latest Information Update: 29 Mar 2017
At a glance
- Drugs Aflibercept (Primary)
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- 23 Mar 2017 Planned number of patients changed from 31 to 40.
- 23 Mar 2017 Status changed from not yet recruiting to recruiting.
- 07 Oct 2016 New trial record